Histogenics Corporation to Announce Second Quarter 2017 Financial Results on August 10, 2017
July 27 2017 - 8:30AM
Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine
company focused on developing and commercializing products in the
musculoskeletal space, announced it will release its financial and
operational results for the quarter ended June 30, 2017, on August
10, 2017 before the market opens.
Histogenics’ management will host a conference
call on Thursday, August 10, 2017 at 8:30 a.m. EDT. A
question-and-answer session will follow Histogenics’ remarks.
To participate on the live call, please dial (877) 930-8064
(domestic) or (253) 336-8040 (international) and provide the
conference ID “37210066” five to ten minutes before the start of
the call.
A live audio webcast of the presentation will be
available via the “Investor Relations” page of the Histogenics
website, www.histogenics.com. A replay of the webcast will be
archived on Histogenics’ website for approximately 45 days
following the presentation.
About Histogenics
Corporation
Histogenics is a leading regenerative medicine
company developing and commercializing novel tissue therapies that
may offer more rapid and durable recoveries for patients with pain
and loss of function due to musculoskeletal conditions.
Histogenics’ regenerative medicine platform combines
expertise in cell processing, scaffolding, tissue engineering and
bioadhesives to create tissue ex-vivo. Histogenics’ first
investigational product candidate, NeoCart is designed to treat
cartilage defects in the knee. The Company recently completed
enrollment of its NeoCart Phase 3 clinical trial and expects to
report topline data in the third quarter of 2018. NeoCart is
designed to exhibit characteristics of articular, hyaline cartilage
prior to and upon implantation into the knee and therefore does not
rely on the body to make new cartilage. As a result, NeoCart
is the only product in development or on the market with a one-year
primary superiority endpoint as compared to the standard of
care. There are more than 500,000 or more knee cartilage
procedures in the United States each year, with many healthy active
adults avoiding treatment as they seek other alternatives.
Left untreated, even a small cartilage defect can expand in
size and progress to debilitating osteoarthritis, ultimately
necessitating a joint replacement procedure. Osteoarthritis
is more common in adults over the age of 50, but the condition and
precursors of the condition can be observed much earlier, and
cartilage damage is believed to be one of the leading contributors
of this disease. For more information, please visit
www.histogenics.com.
Contact:
Investor Relations
Tel: +1 (781) 547-7909
InvestorRelations@histogenics.com
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Sep 2023 to Sep 2024